Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Type Condition

    New Ulm, MN

    Search
    New Ulm, MN
    Show Map
    Map View
    New Ulm, MN
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      145 Clinical Paid Trials near New Ulm, MN

      Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      WTX-124 + Pembrolizumab for Solid Tumors

      Maple Grove, Minnesota
      This trial tests a new medicine called WTX-124, alone and with pembrolizumab, in patients with severe forms of skin and kidney cancer. WTX-124 helps the immune system attack cancer cells, and pembrolizumab makes it easier for the immune system to see these cells.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Active Malignancy, Pneumonitis, Autoimmune, Others
      Must Not Be Taking:Steroids, Immunosuppressants

      150 Participants Needed

      Trametinib + Everolimus for Recurrent Brain Cancer

      Minneapolis, Minnesota
      This phase I trial studies the side effects and best dose of trametinib and everolimus in treating pediatric and young adult patients with gliomas that have come back (recurrent). Trametinib acts by targeting a protein in cells called MEK and disrupting tumor growth. Everolimus is a drug that may block another pathway in tumor cells that can help tumors grow. Giving trametinib and everolimus may work better to treat low and high grade gliomas compared to trametinib or everolimus alone.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:1 - 25

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, HIV, Hepatitis B/C, Others
      Must Not Be Taking:CYP3A4/5 Inducers, Herbal Meds

      50 Participants Needed

      NAN-101 for Heart Failure

      Minneapolis, Minnesota
      This trial tests a new heart treatment given directly into the heart's blood vessels. It aims to help patients with severe heart failure who have significant symptoms and limited physical activity. The treatment is designed to improve heart function and quality of life.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Ischemic Cardiomyopathy, Cardiac Surgery, Others
      Must Be Taking:Beta Blockers, ACE Inhibitors

      17 Participants Needed

      Fimepinostat for Brain Cancer

      Minneapolis, Minnesota
      This trial studies how well fimepinostat works in treating patients with newly diagnosed diffuse intrinsic pontine glioma, or medulloblastoma, or high-grade glioma that have come back. Fimepinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Early Phase 1
      Age:3 - 39

      Key Eligibility Criteria

      Disqualifiers:Diabetes, HIV, Cardiac Arrhythmia, Others
      Must Not Be Taking:HDAC Inhibitors, PI3K Inhibitors

      30 Participants Needed

      GP-2250 + Gemcitabine for Pancreatic Cancer

      Minneapolis, Minnesota
      This trial tests a new drug, GP-2250, combined with gemcitabine for patients with advanced pancreatic cancer who haven't responded to other treatments. The goal is to see if this combination works better than existing options. Gemcitabine has been widely used in the treatment of advanced pancreatic cancer, often in combination with other drugs to improve results.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Active Malignancy, Lung Disease, Cardiovascular Disease, Others
      Must Be Taking:Gemcitabine

      64 Participants Needed

      Ketoconazole for Cancer-related Rash

      Saint Louis Park, Minnesota
      This trial studies how well ketoconazole, a skin-applied medication, works in treating rashes caused by cancer treatments. It targets cancer patients who have rashes from specific cancer medications. Ketoconazole may help by blocking certain hormones that cause the rash. Erlotinib is a potent medication approved for treatment of lung and pancreatic cancer.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Early Phase 1

      Key Eligibility Criteria

      Disqualifiers:Allergy To Ketoconazole, Sulfites
      Must Be Taking:EGFR Inhibitors

      58 Participants Needed

      DAY101 for Brain Tumor

      Minneapolis, Minnesota
      This research study is studying a drug Tovorafenib/DAY101 (formerly TAK-580, MLN2480) as a possible treatment a low-grade glioma that has not responded to other treatments. The name of the study drug involved in this study is: • Tovorafenib/DAY101 (formerly TAK-580, MLN2480)
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1
      Age:1 - 25

      Key Eligibility Criteria

      Disqualifiers:NF1, Major Disease, Cardiovascular, Others
      Must Not Be Taking:Strong CYP2C Inducers, Gemfibrozil

      44 Participants Needed

      NX-019 for EGFR-Mutant Cancer

      Saint Louis Park, Minnesota
      This trial is testing NX-019, a new drug, in patients with advanced or metastatic EGFR-mutant cancer. The drug aims to block a protein that helps cancer cells grow, potentially slowing down or stopping the cancer. NRC-AN-019 has shown better antitumor activity than Lapatinib in pre-clinical breast cancer models.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:C797X EGFR Mutations, Uncontrolled Diabetes, Others
      Must Not Be Taking:Strong CYP3A Inhibitors, Proton Pump Inhibitors

      258 Participants Needed

      ABBV-319 for Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

      Minneapolis, Minnesota
      This trial is testing a new drug called ABBV-319 for adults with certain blood cancers that have come back or didn't respond to treatment. The drug is given in regular intervals, starting with small amounts and gradually increasing to find the most effective amount. The goal is to see if ABBV-319 is safe and effective in reducing cancer activity.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Active CNS Disease, Active Infection, ECOG >= 2

      154 Participants Needed

      T-DXd Combinations for Breast Cancer

      Minneapolis, Minnesota
      This trial is testing T-DXd with other treatments in patients with a specific type of advanced breast cancer that has low levels of HER2. The study aims to find the best dose and see how well the treatment works and how safe it is. T-DXd is a new treatment that has shown promising outcomes in various studies for advanced breast cancers with different levels of HER2.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Cardiovascular Disease, ILD, CNS Metastases, Others
      Must Not Be Taking:IV Antibiotics, Antivirals

      138 Participants Needed

      SPYK04 for Solid Cancers

      Minneapolis, Minnesota
      This trial aims to evaluate the safety and initial effectiveness of a new treatment. Specific details about the intervention, patient group, and how the treatment works are not provided.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Cardiovascular Disease, CNS Malignancy, ILD, Others

      113 Participants Needed

      LY3484356 for Breast Cancer

      Minneapolis, Minnesota
      The reason for this study is to see if the study drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced or metastatic breast cancer or endometrial cancer.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Infections, CNS Cancer, Others
      Must Not Be Taking:Everolimus, Alpelisib

      500 Participants Needed

      Herbal Snuff for Smokeless Tobacco Use

      Minneapolis, Minnesota
      Our goal in this study is to investigate the extent of endogenous nitrosation of nornicotine in smokeless tobacco users as a function of nornicotine content in smokeless products. This study will lead to an understanding of the endogenous formation of NNN from nornicotine in humans, and will also investigate the effect of the reduction of nornicotine content in smokeless tobacco on the extent of endogenous NNN formation. The knowledge gained in this study will lead to the development of recommendations for the regulation, or potentially elimination, of nornicotine in smokeless tobacco products in order to minimize exposure to NNN in the users of these products.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Immune Disorders, Respiratory Diseases, Kidney, Others
      Must Not Be Taking:Metabolic Enzyme-affecting Drugs

      55 Participants Needed

      Proteomics Analysis for Heart Valve Disease

      Minneapolis, Minnesota
      The purpose of the HALT Biomarkers study are to identify a panel of circulating proteins that discriminates between patients with and without Hypo-Attenuated Leaflet Thickening (HALT) and can be used to supplement the diagnosis of HALT; to characterize changes in circulating proteins after treatment of HALT with systemic anticoagulation; and to identify circulating proteins that predict the occurrence of HALT. The study population will be adult patients undergoing transfemoral transcatheter aortic valve replacement (TAVR) for severe aortic stenosis (AS) or bioprosthetic valve degeneration. Enrollment will continue until 30 patients with HALT are identified for completion of phase 1. Based on a HALT incidence rate of 10%, we anticipate enrolling 300 patients. Patients are enrolled prior to undergoing transfemoral TAVR. Blood samples, clinical data and echocardiograms will be collected at the following timepoints: baseline (pre-TAVR, T0), post-TAVR (pre-discharge, T1), 30-day follow-up (window 3-9 weeks, T2), and 6-month follow-up (T3). Cardiac 4D CT will be performed at the 30-day follow-up visit to screen for the occurrence of HALT. Patients with HALT will be treated with systemic anticoagulation for 5-6 months, at which point a follow-up CT scan and blood sample will be obtained. Control subjects will also undergo a 6-month study visit with blood sample collection. The study will be conducted within two phases. Phase 1 will serve as a derivation / discovery study in which candidate protein biomarkers of HALT will be identified. Once this is successfully completed, a second cohort will be enrolled within phase 2. Phase 2 will be performed under the auspices a future contract or amendment and will seek to cross-validate the initial study findings.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:65+

      Key Eligibility Criteria

      Disqualifiers:Chronic Kidney Disease, Hypercoagulable State, Others
      Must Not Be Taking:Anticoagulants

      300 Participants Needed

      RO7497372 for Diabetic Macular Edema

      Saint Louis Park, Minnesota
      This study will assess the safety and tolerability of RO7497372 in participants with DME. The study consists of 2 parts. Part 1 will test multiple-ascending doses of RO7497372 after unilateral intravitreal (IVT) administration in participants with DME. The main purpose of Part 1 is to provide data for RO7497372 safety and tolerability, as well as to characterize the ocular and systemic pharmacokinetics (PK), systemic anti-drug antibodies (ADA), and duration of target engagement, i.e., the pharmacodynamics (PD) in aqueous humor (AH) and blood. Part 2 will evaluate the safety, tolerability, PK, and PD of two dose strengths of RO7497372 (low dose and high dose), identified as safe and tolerated in Part 1.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Active Cancer, Stroke, Myocardial Infarction, Uncontrolled Glaucoma, Others
      Must Not Be Taking:Anti-IL-6 Treatments

      176 Participants Needed

      PF-07799544 for Cancer

      Saint Louis Park, Minnesota
      This trial tests a new cancer medicine, PF-07799544, taken regularly as a tablet. It is for people with advanced solid tumors who haven't responded to other treatments. The medicine may be used alone or with other drugs to improve its effectiveness.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:16+

      Key Eligibility Criteria

      Disqualifiers:Brain Metastasis, Retinal Vein Occlusion, Others

      124 Participants Needed

      Tagraxofusp for Blood Cancers

      Minneapolis, Minnesota
      Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims to examine the safety of this novel agent in pediatric patients with relapsed/refractory hematologic malignancies. The mechanism by which tagraxofusp kills cells is distinct from that of conventional chemotherapy. Tagraxofusp directly targets CD123 that is present on tumor cells, but is expressed at lower or levels or absent on normal hematopoietic stem cells. Tagraxofusp also utilizes a payload that is not cell cycle dependent, making it effective against both highly proliferative tumor cells and also quiescent tumor cells. The rationale for clinical development of tagraxofusp for pediatric patients with hematologic malignancies is based on the ubiquitous and high expression of CD123 on many of these diseases, as well as the highly potent preclinical activity and robust clinical responsiveness in adults observed to date. This trial includes two parts: a monotherapy phase and a combination chemotherapy phase. This design will provide further monotherapy safety data and confirm the FDA approved pediatric dose, as well as provide safety data when combined with chemotherapy. The goal of this study is to improve survival rates in children and young adults with relapsed hematological malignancies, determine the recommended phase 2 dose (RP2D) of tagraxofusp given alone and in combination with chemotherapy, as well as to describe the toxicities, pharmacokinetics, and pharmacodynamic properties of tagraxofusp in pediatric patients. About 54 children and young adults will participate in this study. Patients with Down syndrome will be included in part 1 of the study.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:1 - 21

      Key Eligibility Criteria

      Disqualifiers:CNS Disease, Active Infection, DNA Fragility, Others
      Must Not Be Taking:Corticosteroids, Investigational Drugs, Anti-cancer Agents

      54 Participants Needed

      Combination Therapy for Pancreatic Cancer

      Saint Louis Park, Minnesota
      This trial tests a new drug, AB680, combined with three other drugs in patients with advanced pancreatic cancer. The goal is to enhance the immune system's response and use chemotherapy to fight the cancer.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Cardiovascular Disease, Autoimmune Disease, Others
      Must Not Be Taking:Immunosuppressants, Corticosteroids

      196 Participants Needed

      Continuous Glucose Monitoring for Gestational Diabetes

      Saint Louis Park, Minnesota
      The goal of this clinical trial is to use continuous glucose monitoring (CGM) to quickly detect and manage high blood sugar in pregnant women, early in pregnancy. The main questions it aims to answer are: (1) any problems for the baby, such as being too large for their age, shoulder injuries (like broken bones), high bilirubin levels needing light treatment, low blood sugar, or needing to stay in the NICU; (2) any high blood pressure issues for the mother during pregnancy.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Gestational Diabetes, Gastric Bypass, Diabetes, Others
      Must Not Be Taking:Corticosteroids, Insulin, Metformin, Others

      6000 Participants Needed

      Veteran Social Support for Smoking Cessation

      Minneapolis, Minnesota
      This study is recruiting Veterans who currently smoke cigarettes and support persons who are nominated by the Veterans. The purpose of this study is to assist Veterans with smoking cessation by asking Veterans to choose a support person who will assist them with the quitting process, or who may assist them with the quitting process once the Veteran is ready to quit smoking sometime in the future. Study staff will assess how much or how little social support during the Veteran's quitting process is helpful to the Veteran. This information will help us come up with new ways to help Veterans quit smoking that are better tailored to their needs.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:No Phone Contact, Others
      Must Not Be Taking:Cessation Medications

      2376 Participants Needed

      Why Other Patients Applied

      "As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

      IZ
      Healthy Volunteer PatientAge: 38

      "I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

      FF
      ADHD PatientAge: 31

      "I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

      AG
      Paralysis PatientAge: 50

      "My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

      HZ
      Arthritis PatientAge: 78

      "I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

      ZS
      Depression PatientAge: 51
      Match to a Trial

      Cryo-compression for Rotator Cuff Injury

      Plymouth, Minnesota
      Effective post - operative pain control following orthopedic surgical procedures without excessive reliance upon opioid pain medication has garnered increased attention in recent years. This study will evaluate the utilization of a non-invasive, novel cryo - compression, post-operative modality to improve pain control versus standard ice wraps in the immediate post-operative phase of arthroscopic rotator cuff surgery via a randomized controlled study design. Furthermore, if this study demonstrates improved pain control, improved quality of life and decreased opioid usage with the intermittent cold compression unit, recommendations may be considered for system-wide utilization.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Osteoarthritis, Obesity, Addiction, Others
      Must Not Be Taking:Opioids

      100 Participants Needed

      CMAP App for Pressure Sore Prevention

      Minneapolis, Minnesota
      For Veterans with spinal cord injury who use a wheelchair, pressure injuries related to sitting are a significant daily threat to well-being. Pressure injuries are costly to treat, negatively impact quality of life and community participation, and can be life threatening. Moving or shifting at regular intervals in the wheelchair redistributes harmful pressure and reduces risk for skin breakdown, yet these movements are a challenge to perform consistently. The challenge exists due to lack of sensation to let the individual know they need to shift their weight. Pressure mapping provides a detailed visual representation of pressure distribution and can compensate for impaired sensation. Pressure mapping feedback delivered on-demand on mobile platforms can potentially increase effectiveness in carrying out behaviors to reduce risk for pressure injury when used during clinician-delivered education to set goals and monitor progress and when used at home as a self-management strategy.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Active Pressure Injury, Flap Surgery, Customized Cushion, Others

      46 Participants Needed

      WiSE CRT System for Heart Failure

      Minneapolis, Minnesota
      This study is a prospective, multi-center, pivotal trial to study the safety and efficacy of the WiSE-CRT System for Cardiac Re-synchronization Therapy.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:RBBB, Renal Dysfunction, Atrial Fibrillation, Others
      Must Be Taking:Guideline Directed Medical Therapy

      300 Participants Needed

      Sauna Detoxification for Firefighters

      Minneapolis, Minnesota
      The purpose of the study is to evaluate whether sauna use after active-duty firefighting is effective in reducing exposure to certain harmful chemicals called polycyclic aromatic hydrocarbons (PAHs). PAHs are found in soot and several types are known to be carcinogens. This study is a cross-sectional pilot study that will be performed in active-duty firefighters. The firefighters will be subdivided into those who will use a sauna immediately after fighting a fire versus those who will not, the latter of which will serve as a metabolism control group. There will thus be two comparison groups within the study: 1) active-duty firefighters using a sauna after fire suppression (sauna group); 2) active-duty firefighters not using a sauna after fire suppression (metabolism control).
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Limited Firefighting, Sauna Contraindications, Pregnancy, Others

      60 Participants Needed

      Modafinil for Cognition in Healthy Subjects

      Minneapolis, Minnesota
      The goal of this clinical is to learn more about decision making in psychosis spectrum disorders, like schizophrenia. The investigators will ask people who do not have psychosis to take a single dose of modafinil and then complete some brain games on the computer that measure decision making. They hope to improve our understanding of psychosis to help people in the future. The main research questions are: Does a single dose of modafinil change how people play the brain games? Does a single dose of modafinil change brain activity? Participants will: Complete an interview and self-report questionnaires. Complete safety screening activities, like a blood draw, a urine drug test, and an alcohol breathalyzer test. Take a single dose of modafinil. Complete brain games while wearing an electroencephalography (EEG) cap, before and after taking the single dose of modafinil. EEG measures electrical activity in the brain.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:18 - 35

      Key Eligibility Criteria

      Disqualifiers:Neurological Disorder, Heart Disease, Hypertension, Pregnancy, Psychotic Disorder, Others
      Must Not Be Taking:Ketamine, MAOIs, Warfarin, Others

      103 Participants Needed

      Denosumab to Prevent Breast Cancer in Women With BRCA1 Mutation

      Saint Paul, Minnesota
      This phase III trial compares denosumab to placebo for the prevention of breast cancer in women with a BRCA1 germline mutation. A germline mutation is an inherited gene change which, in the BRCA1 gene, is associated with an increased risk of breast and other cancers. Denosumab is a monoclonal antibody that is used to treat bone loss in order to reduce the risk of bone fractures in healthy people, and to reduce new bone growths in cancer patients whose cancer has spread to their bones. Research has shown that denosumab may also reduce the risk of developing breast cancer in women carrying a BRCA1 germline mutation.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:25 - 55
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Bilateral Mastectomy, Ovarian Cancer, Breast Cancer, Invasive Cancer, Others
      Must Not Be Taking:Tamoxifen, Raloxifene, Aromatase Inhibitors

      300 Participants Needed

      LevoCept for Birth Control

      Minneapolis, Minnesota
      To assess the contraceptive efficacy (prevention of pregnancy) of LevoCept
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 3
      Age:< 45
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Cancer, Liver Disease, Others
      Must Not Be Taking:Estrogen, Progesterone, Testosterone, Others

      1525 Participants Needed

      Pneumococcal Vaccine for Pneumonia Prevention

      Minneapolis, Minnesota
      This study is a Phase 3, randomized, modified double-blind study which aims to document the safety profile of the PCV21 vaccine (investigational pneumococcal vaccine) compared to a licensed 20-valent pneumococcal conjugate vaccine in infants aged from approximately 2 months (42 to 89 days). The study duration per participant will be up to approximately 19 months. The study vaccines (either PCV21 or 20vPCV) will be administered at approximately 2, 4, 6 and 12 to 15 months of age. Routine pediatric vaccines will be given as per local recommendations. There will be 6 study visits: Visit (V)01, V02 separated from V01 by 60 days, V03 separated from V02 by 60 days, V04 separated from V03 by 30 days, V05 at 12 months of age until 15 months of age, V06 separated from V05 by 30 days.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:42 - 89

      Key Eligibility Criteria

      Disqualifiers:Immunodeficiency, Seizures, Bleeding Disorders, Others
      Must Not Be Taking:Immunosuppressants, Anticoagulants, Corticosteroids, Others

      2320 Participants Needed

      mRNA-1403 for Stomach Flu

      Minneapolis, Minnesota
      The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1403, and to demonstrate the efficacy of mRNA-1403 to prevent protocol-defined moderate or severe norovirus acute gastroenteritis (AGE) associated with vaccine matched genotypes.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Chronic GI Disease, Immunodeficiency, Others
      Must Not Be Taking:Immunosuppressants, Blood Products

      28000 Participants Needed

      RSV Vaccine for Infants and Toddlers

      Minneapolis, Minnesota
      This study is a phase III, randomized, observer-blind, placebo-controlled, multinational, multi-center study to be conducted in approximately 6300 children 6 months to \< 22 months of age. The purpose of the study is to evaluate the efficacy, immunogenicity, and safety of Respiratory Syncytial Virus Toddler (RSVt) vaccine administered by intranasal route compared to placebo. Eligible participants will be randomized in a 1:1 ratio to receive 2 intranasal administrations of either the RSVt vaccine or placebo. Study duration will be 24 months for each participant. The safety follow-up will start after the first vaccination and up to the end of the study.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:6 - 21

      Key Eligibility Criteria

      Disqualifiers:Immunodeficiency, Wheezing, Chronic Illness, Others
      Must Not Be Taking:Immunosuppressants, Corticosteroids, Others

      6300 Participants Needed

      12345

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do clinical trials in New Ulm, MN pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do clinical trials in New Ulm, MN work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials in New Ulm, MN 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in New Ulm, MN is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in New Ulm, MN several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a medical study in New Ulm, MN?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest clinical trials in New Ulm, MN?

      Most recently, we added Adalimumab + Verapamil for Type 1 Diabetes, LevoCept for Birth Control and Epidural Stimulation for Spinal Cord Injury to the Power online platform.

      Popular Searches

      By Condition

      Depression Clinical Trials in Minnesota

      Anxiety Clinical Trials in Minnesota

      Schizophrenia Clinical Trials in Minnesota

      ADHD Clinical Trials in Minnesota

      Bipolar Disorder Clinical Trials in Minnesota

      Multiple Sclerosis Clinical Trials in Minnesota

      Autism Clinical Trials in Minnesota

      Treatment Resistant Depression Clinical Trials in Minnesota

      Borderline Personality Disorder Clinical Trials in Minnesota

      Social Anxiety Disorder Clinical Trials in Minnesota

      Parkinson's Disease Clinical Trials in Minnesota

      Alzheimer's Disease Clinical Trials in Minnesota

      By Location

      Clinical Trials near Minneapolis, MN

      Clinical Trials near Rochester, MN

      Clinical Trials near Saint Paul, MN

      Clinical Trials near Duluth, MN

      Clinical Trials near Saint Louis Park, MN

      Clinical Trials near Edina, MN

      Clinical Trials near Maplewood, MN

      Clinical Trials near Fridley, MN

      Clinical Trials near Coon Rapids, MN

      Clinical Trials near Burnsville, MN

      Clinical Trials near Woodbury, MN

      Clinical Trials near Saint Cloud, MN

      Other People Viewed

      By Subject

      Top Breast Cancer Clinical Trials near Baltimore, MD

      195 Clinical Trials near Fairfield, CT

      209 Clinical Trials near Hampton, VA

      Top Dental Implants Clinical Trials

      36 Depression Trials near Denver, CO

      Top Diabetes Clinical Trials near Evansville, IN

      Top Colorectal Cancer Clinical Trials near Anaheim, CA

      Top Urothelial Carcinoma Clinical Trials

      Top Gastric Cancer Clinical Trials

      Top Clinical Trials near Boise, ID

      Top Treatment for Intervention Clinical Trials

      197 Clinical Trials near Baltimore, MD

      By Trial

      GAINS Technology for Autism

      Family Communication Intervention for Dilated Cardiomyopathy

      Cardiac Screening for Hodgkin's Lymphoma Survivors

      Vemurafenib + Cobimetinib for Thyroid Cancer

      Ladarixin + Sotorasib for Advanced Non-Small Cell Lung Cancer

      Cemiplimab for Merkel Cell Carcinoma

      Omega 3 Fatty Acids for Breast Cancer Prevention

      Immunotherapy + Radiation for Hormone-Sensitive Breast Cancer

      RO7121932 for Multiple Sclerosis

      Home-Based Integrated Care Nudge for Heart Failure

      Point-of-Care Ultrasound for Heart Failure

      Online Therapy + Sauna Blanket for Insomnia